According to new reports, the U.S. Food and Drug Administration is about to approve exa-cel – the very first DNA-editing treatment aiming to relieve symptoms of sickle cell disease – for use in the United States.
The treatment reportedly uses CRISPR, a Nobel-prizing winning technology, to conduct the gene therapy.
Sickle cell treatments with exa-cel will purportedly cost approximately $2 million per patient, Wall Street analysts estimate.
The FDA is expected to release approval of the treatment by the end of the week.
